Some QOL benefits for second-line Halaven in breast cancer
This article was originally published in Scrip
Eisai has presented new quality of life (QOL) data from one of the main Phase III trials with its breast cancer drug Halaven (eribulin mesylate) that it will be hoping may boost the competitive position of the novel microtubule dynamics inhibitor in the earlier line treatment of metastatic disease.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.